Daily Archives: February 9, 2022

Holocaust jokes have their place but require empathy – The Irish Times

Posted: February 9, 2022 at 2:11 am

At a time when mainstream politicians across the world are openly lobbing racist grenades into the debating chambers of cable news and social media, why do famous comedians still tell Holocaust jokes and can this subject ever morally be the target for comedy? Sometimes yes, mostly no.

Coming from a Jewish refugee family (my mother is a Holocaust survivor and many other family members were murdered), I am naturally acutely sensitive to jokes made about this subject. My family is divided on the question of Holocaust humour. In my work as the founder of Holocaust Awareness Ireland, I occasionally use humour myself. It helps to break the tension with the audience. Without it, the pitch-black intensity of the Holocaust can make the facts hard to absorb, leaving the audience numb.

But jokes about the Holocaust are among the hardest for any comedian to pull off. Except for neo-Nazis and Holocaust deniers you are likely to offend everyone else in the audience. Gratuitous, indescribable cruelty inflicted on millions of civilians and the murder of six million Jews, half a million Roma and Sinti, and tens of thousands of homosexuals, the disabled and political prisoners is not an obvious subject for comedy. Especially as its still in living memory.

Holocaust comedy is a high-wire act given the golden rule of comedy: it has to be funny. Empathy is the key. Jokes at the expense of those who cannot defend themselves only really work when the observation exposes our own vulnerabilities.

Every so often, the question raises its head as another comedian uses the Holocaust to get a laugh. Failure will bring opprobrium and censure, as well as a blaze of publicity; the latter perhaps never wholly unwelcome. This time, the English comedian, Jimmy Carr, has stepped on the proverbial land mine, receiving a widespread backlash. In a recent show on Netflix he tells us that thousands of gypsies died in the Holocaust . . . no one ever wants to talk about that, because no one ever wants to talk about the positives.

Beyond tasteless, Carr succeeds in further demeaning the Traveller and Romany communities, the implication being that they are a marginalised section of society whom no one values, so genocide in their case is a good thing. In an attempt to defend himself, Carr digs a deeper hole for himself by explaining that it was educational and that its a joke about the worst thing thats ever happened in human history, and people say never forget, well this is how I remember.

Except that Carr has shown no empathy for the victims, whose only crime was to be singled out for their ethnicity, just like the Jews. By degrading them today, he questions their right to mourn their unimaginable loss. Humiliating Holocaust victims and their families is an especially despicable act with consequences for them that are more complex than Carr foresees.

If Carr is interested in how to tackle the Holocaust as a stand-up comedian, he should turn to Ricky Gervais. In a double episode of Jerry Seinfelds series of Comedians in Cars Getting Coffee in 2019, Gervais tells two Holocaust jokes. The first is a version of a well-worn gag where a Holocaust survivor goes to God and tells him a Holocaust joke. God replies that it isnt funny whereupon the Holocaust survivor counters, Youd have to have been there.

The second joke has the commandant of Auschwitz allowing a group of Jewish prisoners their freedom for Christmas. As they are filing out the last one says to his captor, But we dont celebrate Christmas.

Gervais comedic instincts around the Holocaust are humane. His first joke is sophisticated and works at many levels, especially as Gervais is well known as an atheist. His second turns the butt of the joke into a hero; someone not prepared to accept freedom at any cost, especially if the price is giving up that part of him that led to his incarceration.

Both jokes show great sympathy for the survivors. They also work by depicting the absurdity of the Holocaust. This was a structure that Roberto Benigni deployed in his 1997 double Oscar-winning film Life is Beautiful; a fable that has a father and son incarcerated in a concentration camp, Benigni plays the part of the father. He tries to convince his young son that the Nazis are playing a game in order to shield him from the horror of their circumstances. Benigni commented that this contrived scenario was no more absurd than the realities of life for the victims.

Absurdity and farce were the devices used by Mel Brooks in his classic 1967 film The Producers with Zero Mostel and Gene Wilder, and later in 1983 with To Be or Not to Be in which he starred next to his wife, Anne Bancroft. Interestingly, Chaplins masterful parody of the Nazi regime,The Great Dictator, came out in 1940 before the Holocaust had fully swung into operation.

Perhaps knowledge of the full extent of the horror now precludes satire as a comedy genre in this arena. The events are so extreme that farce seems to connect more viscerally with the audience than satire. This was the heart of the success of the British comedy series Allo Allo!, which ran for 10 years from 1982, itself a parody of a fictional series about the Belgian Resistance, called Secret Army which ran for two years from 1977.

In part two of the Seinfeld episode, Gervais shocks Seinfeld by showing him a black and white picture of a baby boy and asks Seinfeld to guess who it is. At the third attempt Seinfeld guesses correctly: Adolf Hitler. Gervais asks Seinfeld the classic moral teaser: if he could go back in time would he kill him? Look, he says, hes only one. Hes done nothing wrong yet. Hes adorable. The same photograph inspired the great Polish poet, Wislawa Szymborskas, Hitlers First Photograph, a poem that could be about any infants first portrait. Except, of course, we know how this story ends.

The Holocaust is the Everest of comedy topics. It needs years of training to conquer. I am prepared to be made to feel deeply uncomfortable if the joke is clever, tender and empathetic. Most of all, if I can laugh at this inherited trauma, it might mean that it is possible to live a just life in a world where the Holocaust made justice an impossibility for its victims.

Oliver Sears is founder of Holocaust Awareness Ireland

Go here to read the rest:

Holocaust jokes have their place but require empathy - The Irish Times

Posted in Golden Rule | Comments Off on Holocaust jokes have their place but require empathy – The Irish Times

Three tips to help you stay motivated to keep exercising all year long – News24

Posted: at 2:11 am

February. The month of shattered dreams and ambitions. The trainers are gathering dust and chocolate bars have replaced protein bars. The gusto with which we attacked our new year resolutions is a vague memory.

If your motivation to stick to your resolution to exercise more this year is waning, youre not alone. Its suggested around 80% of people will have given up on their new year resolutions by February.

But the reason your motivation wanes might be because you chose the wrong motives and goals to begin with. And research shows us that choosing the right type of goal is the key to keeping us motivated over the long term.

Many of us believe that we need to grimace, contort, sweat and pant our way to a healthier life. So at the beginning of January, we put in a load of effort to help us reach our goals.

Unfortunately, our brain encourages us to avoid physical effort. This is why the excessive effort we use when exercising will work against us in the long run leading us to feel less motivated to exercise by the end of January.

Our brain is constantly monitoring our body for any changes from our resting state, which could mean danger to our health. The more physical effort we use, the more a signal is activated and our brain tells us that the activity just isnt worth the effort and potential risk.

This is why minimising the effort we need to put into exercise may actually better help us stick to our resolutions in the long term. For example, if youre dreading even a fifteen-minute jog, do five minutes instead.

Or if you hate running but enjoy Zumba, do that instead. The golden rule is that the activity youre trying to motivate yourself to do needs to be pleasurable. And research shows were much more likely to do something if it requires less effort especially when were starting new exercise regimes.

The same principle applies to reducing the psychological effort required to exercise, as our brains also encourage us to avoid it to such an extent that, when given the choice, we often prefer physical pain instead. It does this because it wants to save psychological effort for times of emergency.

When it comes to starting a new exercise regime in the new year, things like fitting workouts into our schedule or getting out of bed an hour earlier all require psychological effort. To reduce psychological effort, it may help to minimise needless decision-making.

When its time to exercise, remove decisions like whether to walk or drive to exercise class, or put your trainers in the same place so you dont have to look for them.

Although these sound like small decisions to make, they can all add up to us feeling less motivated to exercise when were required to make them. Research even shows that when we think our goals require little effort to achieve, were more likely to achieve them.

Another basic motivational mistake many of us made in January was to set our goals too far in the future. Many people start exercising to lose a few pounds perhaps to fit into their favourite jeans again. But when the outcome is far in the future, our brains dont associate the motivation (fitting into our jeans) with exercising so were less inclined to exercise.

By choosing a goal that has a more immediate outcome, our brains will associate the outcome positively with exercise because they occur simultaneously. For example, the mood-boosting benefits of exercise occur more quickly than physical health changes so this may be a better motivator for you to keep exercising well past January. In short, make the reason for exercise an immediate one you can achieve and the long-term benefits will follow.

The final motivational fix is switching the type of goal you have. So-called have goals serve little purpose for our motivational brain, which focuses on more important things such as being effective at what we do and making social bonds.

An example of a have goal would be exercising so that you can have a better body. This type of goal is viewed as less important by our brain because it does not help us meet essential goals that help us thrive.

On the other hand, the types of goals that are more likely to keep us motivated are be goals. An example of a be goal would be exercising to be healthy or to be more athletic. Be goals are superior because humans tend to want to bond with other like-minded people based on our identities.

This motivation is thought to have developed in our ancestral past, as forming bonds helped us to survive. So someone may find exercise easier to stick with if theyre doing it as a way to demonstrate their athleticism, for example. As a result, people do a better job of sticking to be goals, compared to other types of goals.

Even if you have fallen off the wagon slightly by the end of January, that doesnt mean you have to give up on your goals entirely. But making some tweaks to them and your approach to exercise may help you better stick to your goals for the rest of the year.

Ian Taylor, Senior Lecturer in Psychology, Loughborough University

This article is republished from The Conversationunder a Creative Commons license. Read the original article.

View post:

Three tips to help you stay motivated to keep exercising all year long - News24

Posted in Golden Rule | Comments Off on Three tips to help you stay motivated to keep exercising all year long – News24

Atopic Dermatitis Treatment, Symptoms & Causes | NIAMS

Posted: at 2:10 am

The most common symptom of atopic dermatitis is itching, which can be severe. Other common symptoms include:

The symptoms can flare in multiple areas of the body at the same time and can appear in the same locations and in new locations. The appearance and location of the rash vary depending on age; however, the rash can appear anywhere on the body.

During infancy and up to 2 years of age, it is most common for a red rash, which may ooze when scratched, to appear on the:

Some parents worry that the infant has atopic dermatitis in the diaper area; however, the condition rarely appears in this area.

During childhood, usually 2 years of age to puberty, it is most common for a red thickened rash, which may ooze or bleed when scratched, to appear on the:

During the teenage and adult years, it is most common for a red to dark brown scaly rash, which may bleed and crust when scratched, to appear on the:

Other common skin features of atopic dermatitis include:

In addition, people with atopic dermatitis often have other conditions, such as:

Researchers continue to study why having atopic dermatitis as a child can lead to the development of asthma and hay fever later in life.

Complications of atopic dermatitis can happen. They include:

See the rest here:
Atopic Dermatitis Treatment, Symptoms & Causes | NIAMS

Posted in Eczema | Comments Off on Atopic Dermatitis Treatment, Symptoms & Causes | NIAMS

Eczema diet tips: Foods to eat and avoid

Posted: at 2:10 am

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Eczema or atopic dermatitis is a condition that causes a person to develop patches of dry, itchy skin on their body. It often develops as a result of inflammation in the body, so eating foods that do not cause inflammation may help reduce symptoms.

While no cure exists, over-the-counter creams and medications that can help to reduce inflammation are available. Sometimes, a doctor may recommend avoiding foods known to make eczema worse.

Some foods may trigger the release of T cells that cause inflammation, as well as immunoglobulin-E or IgE, which is an antibody that the body produces in response to a threat. Foods that contribute to inflammation include nuts, milk, and wheat.

For people with eczema, eating certain foods can trigger the body to release immune system compounds that cause inflammation, which, in turn, contributes to an eczema flare-up. An anti-eczema diet is similar to an anti-inflammatory diet.

Examples of anti-inflammatory foods include:

Eating more of these foods and cutting down on any trigger foods could help to reduce eczema flare-ups.

Food-sensitive eczema reactions will typically occur about 6 to 24 hours after a person eats a particular food. Sometimes, these reactions may be delayed even longer.

To determine what foods may be causing the reaction, a doctor will often recommend an elimination diet. This diet involves avoiding some of the most common foods known to cause eczema.

Before eliminating any foods, a person will need to slowly add each food type into their diet and monitor their eczema for 4 to 6 weeks to determine if they are sensitive to any particular food.

If a persons symptoms get worse after adding a particular food to the diet, they may wish to consider avoiding it in the future. If a persons symptoms do not improve when eliminating a food, they probably do not need to remove it from their diet.

Some common foods that may trigger an eczema flare-up and could be removed from a diet include:

A doctor may also recommend allergy testing. Even if a person is not allergic to a particular food, they may have sensitivity to it and could experience skin symptoms after repeat exposure. Doctors call this reaction food responsive eczema.

People with dyshidrotic eczema, which typically affects the hands and feet, may experience benefits from eating foods that do not contain nickel. Nickel is found in trace amounts in the soil and can, therefore, be present in foods.

Foods that are high in nickel include:

Some people with eczema also have oral allergy syndrome or sensitivity to birch pollen. This means they may have reactions to other foods, including:

People with eczema are more prone to oral allergy syndrome and should speak to their doctor if they have a pollen allergy or experience mild allergic reactions to the above foods.

Research has shown that taking probiotic supplements may reduce the symptoms of eczema. More studies are needed, however, to confirm the effectiveness and dosage required.

Probiotics are available in a variety of supplements, such as the selection available here. If a person is not sure which probiotics to buy, they may find the online reviews helpful and can also talk to their doctor.

Probiotics are also naturally present in many foods. Probiotic foods include:

Other supplements that have been studied include fish oil and Chinese herbal preparations; neither of which made a significant difference in eczema symptoms.

While a persons diet is not always a trigger for eczema, some people may find that their symptoms do get better when they make dietary changes.

Making these changes and monitoring the results can help a person determine whether changing their diet can help them better manage their condition.

If a person does eliminate a large food group, such as wheat-containing products, they may wish to talk to their doctor about supplements to ensure they are not missing out on any essential vitamins and minerals.

Read more:
Eczema diet tips: Foods to eat and avoid

Posted in Eczema | Comments Off on Eczema diet tips: Foods to eat and avoid

AbbVie Wins Yet Another Approval for This Drug – Motley Fool

Posted: at 2:10 am

On Jan. 14, AbbVie's (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn't respond to other medicines.

What led the FDA to approve Rinvoq for its third indication? And how much of a boost could this be for AbbVie's sales? Let's dig into the phase 3 clinical trial results and U.S. moderate-to-severe eczema market to find the answers to these two questions.

Image source: Getty Images.

According to Healthline, eczema is a chronic skin condition often expressed by patches of dry, inflamed, and itchy skin. It's thought that the disease is caused by excessive production of immune system cells that lead to inflammation. Eczema typically begins in early childhood and flares up from time to time.

Common first-line treatments for the condition include antihistamines and topical corticosteroids (TCS). Unfortunately, a majority of patients with moderate-to-severe eczema (55%) cannot control their eczema with their current treatment regimen. This can result in sleep issues and weigh on a patient's quality of life, which is why there's demand for more treatments for the disease.

Fortunately, more treatment options are making their way to the market. One of those treatments is Rinvoq, which was approved last August in the European Union to treat moderate-to-severe eczema.What data is there to support the approval in the EU and most recently in the U.S.?

Rinvoq funded a randomized clinical trial of 901 moderate-to-severe eczema patients. These patients were blindly assigned to either receive 15 milligrams of Rinvoq once daily with TCS, 30 milligrams of Rinvoq each day combined with TCS, or a placebo pill and TCS. The patients were followed over the course of a 16-week period. The more pronounced the reduction in the Eczema Area and Severity Index (EASI), the more effective a treatment was for eczema patients. The EASI is a clinical scale that measures eczema's severity and surface area. A 75% or greater improvement in the EASI is called EASI75, which is the best indication of whether a treatment is effective enough to be approved by regulatory agencies.

Patients taking TCS and the lower dose of Rinvoq were found to have reached at least 75% clearer skin, or EASI75, at a 65% rate at week 16, which was much higher than the 26% rate for the TCS and placebo group at week 16. Even more striking, 77% of patients receiving the higher dose of Rinvoq achieved EASI75 at week 16.

Rinvoq could be a powerful treatment for many patients with eczema. So, what could this mean for pharma stock AbbVie?

First, it's estimated that there are 6.6 million adults in the U.S. with moderate-to-severe eczema. For the sake of conservatism and sparse data being available, I won't include the population of U.S. adolescents with the disease.

Second, although 55% of moderate-to-severe eczema patients aren't satisfied with their treatment plan, I'll assume that approximately 20% of the patient pool could start Cibinqo.This works out to 1.3 million potential patients.

Third, Cibinqo has the benefit of being a pill, which helps patients avoid having to go into clinics and hospitals for injections to treat their condition. On the other hand, the convenience of Cibinqo could be at least partially offset by the fact that the drug is a Janus kinase inhibitor. Due to the increased risk of serious adverse events like blood clots, cancer, and major heart-related issues, the FDA could end up restricting patients to just the lower dose of Cibinqo for safety reasons.

Considering all of these factors, I believe that the drug could capture 6% of the market, or 79,000 patients.

Rinvoq has an annual list price of $68,000. Adjusting for patient assistance programs and negotiations from health insurers, I'll use $20,000 as the net annual price per patient. This equates to just under $1.6 billion in annual revenue potential.

Against the $59.8 billion in revenue that analysts are forecasting for AbbVie this year, this would be a nearly 3% boost to the company's overall revenue. An additional $1.6 billion in annual revenue for AbbVie would represent a 30%+ increase in the company's non-Humira immunology segment revenue over the nearly $4.6 billion in combined Skyrizi and Rinvoq revenue for last year.

AbbVie's 8.5% increase in the dividends per share that it will pay out to shareholders in 2022 brings its dividend increase streak to 50 consecutive years -- including its time as part of Abbott Laboratories. This makes the stock a Dividend King.

AbbVie is trading at a forward price-to-earnings (P/E) ratio of 9.8, which is an appealing valuation considering that the stock's earnings are expected to grow 5% annually in the next five years. Investors can scoop up shares of AbbVie and its market-trouncing, steady 4.1% dividend yield on the cheap. That's what makes the stock an attractive option for income investors at the current $140 share price.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

More:
AbbVie Wins Yet Another Approval for This Drug - Motley Fool

Posted in Eczema | Comments Off on AbbVie Wins Yet Another Approval for This Drug – Motley Fool

(New Report) Baby Ointment Market In 2022 : The Increasing use in Eczema, Heat Rash, Diaper Rash, Dry Skin, Cuts, Insect Bites is driving the growth…

Posted: at 2:10 am

[90 Pages Report] Baby Ointment Market Insights 2022 This report contains market size and forecasts of Baby Ointment in United States, including the following market information:

United States Baby Ointment Market Revenue, 2016-2021, 2022-2027, (USD millions)

United States Baby Ointment Market Sales, 2016-2021, 2022-2027, (K Units)

United States top five Baby Ointment companies in 2020 (%)

The global Baby Ointment market size is expected to growth from USD million in 2020 to USD million by 2027; it is expected to grow at a CAGR of % during 2021-2027.

The United States Baby Ointment market was valued at USD million in 2020 and is projected to reach USD million by 2027, at a CAGR of % during the forecast period.

The Research has surveyed the Baby Ointment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

Leading key players of Baby Ointment Market are

Baby Ointment Market Type Segment Analysis (Market size available for years 2022-2027, Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2027): Massage Oils, Lotions, Medicinal Creams

Regions that are expected to dominate the Baby Ointment market are North America, Europe, Asia-Pacific, South America, Middle East and Africa and others

If you have any question on this report or if you are looking for any specific Segment, Application, Region or any other custom requirements, then Connect with an expert for customization of Report.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

For More Related Reports Click Here :

Cresylic Acid Market In 2022

Band Saw Blades Market In 2022

Go here to read the rest:
(New Report) Baby Ointment Market In 2022 : The Increasing use in Eczema, Heat Rash, Diaper Rash, Dry Skin, Cuts, Insect Bites is driving the growth...

Posted in Eczema | Comments Off on (New Report) Baby Ointment Market In 2022 : The Increasing use in Eczema, Heat Rash, Diaper Rash, Dry Skin, Cuts, Insect Bites is driving the growth…

Eli Lilly nixes Verzenio’s phase 3 HER2-positive early breast cancer trial – FiercePharma

Posted: at 2:10 am

Eli Lilly has made the difficult decision to cull a phase 3 study of Verzenio in HER2-positive early breast cancer, Dan Skovronsky, M.D., Ph.D., chief scientific and medical officer at Lilly, said on a call with investors Thursday.

Details were slim, but Skovronsky blamed the decision on changes in the treatment landscape plus global enrollment challenges.

Importantly, this decision does not change our commitment to an investment in breast cancer, Lillys chief scientist said.

News of the Verzenio trial halt comes a week after Lilly announced it was pulling the plug on Olumiants development in lupus. Separately, Olumiants application in moderate-to-severe atopic dermatitis could be in jeopardy, thanks to a stalemate with the FDA about the exact patient population, the company said last week. Lilly expects regulatory action on Olumiants eczema bid very soon, Skovronsky said Thursday.

RELATED:CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say

During the call,Lilly shed more light on Olumiants regulatory impasse in eczema. Lilly believes Olumiant benefits eczema patients most when used in early treatment, Patrik Jonsson, SVP and president of Lilly immunology and president of Lilly USA, said on the call. The FDA, conversely, currently has the position of saving Olumiant for the refractory patients, where we see the incremental value of Olumiant to be quite limited.

If that doesnt change, a complete response letter is likely, Jonsson said.

Lilly has also submitted Olumiant for approval in alopecia, though ananalyst on Wednesdays call questioned whether safety concerns around the JAK-inhibitor class at large could blunt the drugs ambitions there. Lilly simply said it was encouraged by the data its seen so far, and it highlighted the immense opportunity in the disease.

There are currently no treatments approved for alopecia areata, Jonsson said. We have the opportunity here to be first in disease with Olumiant.

There are about 360,000 patients diagnosed with alopecia in the U.S., some 100,000 of whom would be eligible for treatment with a JAK inhibitor, Jonsson added.

RELATED:UPDATED: Eli Lilly to plow a total of $1.5B into 2 new manufacturing plants

For the fourth quarter, Eli Lillys revenue jumped 8% to $7.9 billion. Excluding COVID-19 antibodies, sales for the last three months of the year climbed 6%. Full-year sales increased 15% to $28.3 billion or 10% after subtracting Lillys pandemic antibodies from the equation.

Last month, The FDAtweakedits emergency nod for Lilly and Regenerons monoclonal antibodies, citing recent data showing the drugs arent effective against omicron. The antibodies are now limited to patients whove been infected with or exposed to a variant susceptible to the therapies.

Lilly snared $1.1 billion in COVID-19 antibody revenue for the fourth quarter. Lilly says it delivered roughly 435,000 doses out of 614,000 in the last three months of the year, with most of the remaining doses already shipped out last month.

Lilly credited its fourth-quarter momentum to growth drugs like Trulicity, Taltz, Verzenio, Olumiant, Emgality and more.

"Lillys margin profile represents one of the strongest expansion stories in Pharma, in our opinion, with the potential for mid-teens EPS growth, Cantor Fitzgerald analyst Louise Chen wrote in a note to clients Thursday. Her team thinks Lilly is poised to enter a growth period through 2030, helped by multiple readouts for products like donanemab in Alzheimers disease and tirzepatide in Type 2 diabetes.

Lilly has forecasted full-year 2022 sales between $27.8 billion and $28.3 billion.

View post:
Eli Lilly nixes Verzenio's phase 3 HER2-positive early breast cancer trial - FiercePharma

Posted in Eczema | Comments Off on Eli Lilly nixes Verzenio’s phase 3 HER2-positive early breast cancer trial – FiercePharma

Tralokinumab Linked to Overall Quality of Life Improvements in Adolescents with AD – MD Magazine

Posted: at 2:10 am

LEO Pharma announced new 16-week data on tralokinumab-ldrm, stating that it led to significant improvements in itch, sleep interference, anxiety and depression, and overall quality of life among adolescents aged 12-17 years old with moderate-to-severe atopic dermatitis.

The data were presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) 59th Annual Scientific Session in Maui.

Tralokinumab-ldrm was previously approved by the US Food and Drugs Administration (FDA) in December 2021 for the treatment of adults with moderate-to-severe atopic dermatitis. It is the first and only FDA approved biologic that binds to and inhibits the interleukin (IL)-13 cytokine.

The most recent analysis evaluated patient-reported outcomes with the biologic compared to placebo at week 16 during the 52-week monotherapy phase 3 ECZTRA 6 trial.

A total of 100 patients received 150 mg of tralokinumab-ldrm, while 101 received 300 mg of the biologic. Investigators observed that siginificantly more adolescent patients achieved improvements with the biologic every 2 weeks compared to the 100 patients who received placebo.

A 4-point improvement in adolescent Worst Daily Pruritus Numeric Rating Scale (NRS) was seen in 23.2% of patients receiving tralokinumab-ldrm 150 mg (P<0.001), 25.0% of those in the tralokinumab-ldrm 300 mg group (P<0.001), and 3.3% placebo, while a 6-point improvement in Childrens Dermatology Life Quality Index (CDLQI) was recorded in 31.0% of patients receiving tralokinumab-ldrm 150 mg (P=0.029), 39.5% tralokinumab-ldrm 300 mg (P<0.001), and 15.9% placebo.

Additionally, a 6-point improvement in Patient Oriented Eczema Measure (POEM) was reported in 38.7% of the tralokinumab-ldrm 150 mg group (P<0.001), 46.8% of the tralokinumab-ldrm 300 mg group, (P<0.001), and 10.5% of the placebo group. The biologic was also associated with greater improvement than placebo in eczema-related sleep NRS.

Currently, Tralokinumab-lfrm is not FDA approved in adolescents, and its efficacy and safety have not been full evaluated.

Read more here:
Tralokinumab Linked to Overall Quality of Life Improvements in Adolescents with AD - MD Magazine

Posted in Eczema | Comments Off on Tralokinumab Linked to Overall Quality of Life Improvements in Adolescents with AD – MD Magazine

Weather Headlines for Thursday (x3): The path of the heavy rain, Facial Eczema? Cooler southerlies in the south – WeatherWatch.co.nz

Posted: at 2:10 am

Heavy rain South Island moves to the North Island Sunday

Its all about the rain, the South Island in particular the West Coast sees heavy rain today and Friday, inland Canterbury may actually see some heavy rain into the second half of Friday before starting to ease overnight. Heavy rain moves to the upper South Island (Tasman, Nelson and perhaps Marlborough) on Saturday then heavy rain potential shifts to the North Island on Sunday and continues there early next week. There is still room for change here so not everything is set in stone just yet. More at this link here.

High humidity and rain potential may bring facial eczema

With the dry weather we have had for the North Island lately and now high humidity plus the potential for high amounts of rain coming up this leads to the potential for facial eczema in livestock. Something to take note of.

Relief is coming in the south

Relief from hot temperatures is starting to move in today for the South Island with southerly winds. The lower South Island will notice this today, the upper South Island tomorrow. The North Island remains very hot then starts to see some relief later into Sunday and Monday.

Continue reading here:
Weather Headlines for Thursday (x3): The path of the heavy rain, Facial Eczema? Cooler southerlies in the south - WeatherWatch.co.nz

Posted in Eczema | Comments Off on Weather Headlines for Thursday (x3): The path of the heavy rain, Facial Eczema? Cooler southerlies in the south – WeatherWatch.co.nz

Influencer has perfect response to troll who called her ‘obese’ and ‘disgusting’ – indy100

Posted: at 2:10 am

A body-positive influencer shut down an Instagram troll who wrongly criticised her weight.

Australian model and bikini designer Karina (@karinairby) often posts uplifting content to her 1.2 million followers to encourage women to appreciate their bodies, no matter the size or shape.

On Sunday, the 29-year-old took to the platform to hit back at a troll who called her "obese" and "disgusting."

Putting them on blast, Karina launched into the perfect response to "publicly attempt to educate [them] on the female body!"

"Clearly youve had one too many in counters with blow-up dolls and watched a little too much pretty porn and its warped perception," she said [sic].

"Buckle up buttercup. Youre in for a rude shock!

Sign up to our free Indy100 weekly newsletter

"This is not repulsive and very far from obese. Yeah, I may have cellulite, eczema and some meat on my bones. But Im a young healthy female that you could be so lucky to have a chance with."

"99.9% of women dont look like a Barbie doll.

"99.9% of women have cellulite, lumps, dumps, scars, stretch marks, muscle and skin.

"99.9% of women would never date you because of your repulsive outlook on what a female should look like.

Karina continued: "And as for people supporting what I stand for (body positivity and acceptance).

"Perhaps if more people where being themselves online and companies shared and marketed different body types youd be better educated by now.

"Im glad we got to have this chat."

Overnight, the Instagram post racked almost 30,000 likes and hundreds of comments praising the influencer for stepping up and shutting them down.

"Honestly how dare they use a reference from the office as their name, only to spew blasphemy against our goddess," one joked.

Another added: "Youre sper brave! Youre an inspiration! Youre WOMAN!"

While one said they "always applaud your response to these."

Indy100 reached out to Karina for comment.

Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

Link:
Influencer has perfect response to troll who called her 'obese' and 'disgusting' - indy100

Posted in Eczema | Comments Off on Influencer has perfect response to troll who called her ‘obese’ and ‘disgusting’ – indy100